Interplay Between Genomic Alterations and Androgen Receptor Signaling During Prostate Cancer Development and Progression

Hormones and Cancer

Volumn 4, Issue 2, 2013, Pages 61-69

  Nyquist, Michael D ^a,b   Dehm, Scott M ^a,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; BICALUTAMIDE; ENZALUTAMIDE;

ANDROGEN DEPRIVATION THERAPY; CANCER GENETICS; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; GENE AMPLIFICATION; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN GENOME; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION;

EID: 84874426546     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-013-0131-4     Document Type: Review

References (60)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer Statistics, 2012. CA Cancer J Clin 62(5): 283-298.
2. Garraway L, Sellers WR (2006) Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer 6(8): 593-602.
3. Bono JSD, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21): 1995-2005.
4. Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13): 1187-1197.
5. Rubin M, Maher C, Chinnaiyan AM (2011) Common gene rearrangements in prostate cancer. J Clin Oncol 29(27): 3659-3668.
6. Taylor BS, Schultz N, Hieronymus H et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1): 11-22.
7. Grasso CS, Wu Y-M, Robinson DR et al (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487(7406): 239-243.
8. Friedlander TW, Roy R, Tomlins S et al (2012) Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res 72(3): 616-625.
9. Berger MF, Lawrence MS, Demichelis F et al (2011) The genomic complexity of primary human prostate cancer. Nature 470(7333): 214-220.
10. Beltran H, Yelensky R, Frampton GM et al (2012) Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol S0302-2838(12): 01006-01008.
11. Wang Q, Li W, Liu XS, Carroll JS et al (2007) A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 27(3): 380-392.
12. Mani R-S, Tomlins S, Callahan K et al (2009) Induced chromosomal proximity and gene fusions in prostate cancer. Science 326(5957): 1230.
13. Lin C, Yang L, Tanasa B et al (2009) Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 139(6): 1069-1083.
14. Haffner MC, Aryee MJ, Toubaji A et al (2010) Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 42(8): 668-675.
15. Tomlins S, Laxman B, Dhanasekaran SM et al (2007) Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448(7153): 595-599.
16. Brenner JC, Chinnaiyan AM (2011) Disruptive events in the life of prostate cancer. Cancer Cell 19(3): 301-303.
17. Yu J, Yu J, Mani R-S et al (2010) An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17(5): 443-454.
18. Richly H, Aloia L, Di Croce L (2011) Roles of the polycomb group proteins in stem cells and cancer. Cell Death Dis 2(9): e204.
19. Chng KR, Chang CW, Tan SK et al (2012) A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. EMBO J 31(12): 2810-2823.
20. Weichert W, Röske, Gekeler V et al (2008) Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98(3): 604-610.
21. Guo C, Chang CC, Wortham M et al (2012) Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways. Proc Natl Acad Sci U S A 109(43): 17603-17608.
22. Barbieri CE, Baca SC, Lawrence MS et al (2012) Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44(6): 685-689.
23. Lupien M, Eeckhoute J, Meyer C et al (2008) FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132(6): 958-970.
24. Lupien M, Brown M (2009) Cistromics of hormone-dependent cancer. Endocr-Relat Cancer 16(2): 381-389.
25. Saraon P, Jarvi K, Diamandis EP (2011) Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem 57(10): 1366-1375.
26. Steinkamp MP, O'Mahony O, Brogley M et al (2009) Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 69(10): 4434-4442.
27. Gottlieb B, Beitel LK, Nadarajah A et al (2012) The androgen receptor gene mutations database: 2012 update. Hum Mutat 33(5): 887-894.
28. Chen CD, Welsbie DS, Tran C et al (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10(1): 33-39.
29. Brooke GN, Bevan CL (2009) The role of androgen receptor mutations in prostate cancer progression. Curr Genom 10(1): 18-25.
30. Li Y, Alsagabi M, Fan D et al (2011) Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res 71(6): 2108-2117.
31. Li Y, Hwang TH, Oseth L et al (2012) AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene 31(45): 4759-4767.
32. Guo Z, Yang X, Sun F et al (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69(6): 2305-2313.
33. Hu R, Dunn T, Wei S et al (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69(1): 16-22.
34. Hörnberg E, Ylitalo EB, Crnalic S et al (2011) Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 6(4): e19059.
35. Mostaghel E, Marck BT, Plymate SR et al (2011) Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17(18): 5913-5925.
36. Hu R, Lu C, Mostaghel E et al (2012) Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 72(14): 3457-3462.
37. Li Y, Chan SC, Brand LJ, Hwang TH, et al. (2013) Truncated AR splice variants and enzalutamide resistance. Cancer Res. doi: 10. 1158/0008-5472. CAN-12-3630.
38. Tepper CG, Boucher DL, Ryan PE et al (2002) Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line characterization of a novel androgen receptor mutation in a relapsed CWR22. Cancer Res 62(22): 6606-6614.
39. Dehm SM, Schmidt LJ, Heemers HV et al (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68(13): 5469-5477.
40. Dehm SM, Tindall DJ (2011) Alternatively spliced androgen receptor variants. Endocr-Relat Cancer 18(5): R183-R196.
41. Sun S, Sprenger CCT, Vessella RL et al (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120(8): 2715-2730.
42. Watson P, Chen YF, Balbas MD et al (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 107(39): 16759-16765.
43. Zhang X, Morrissey C, Sun S et al (2011) Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One 6(11): e27970.
44. Zhou ZX, Sar M, Simental JA et al (1994) A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. J Biol Chem 269(18): 13115-13123.
45. Chan SC, Li Y, Dehm SM (2012) Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem 287(23): 19736-19749.
46. Mehra R, Han B, Tomlins S et al (2007) Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 67(17): 7991-7995.
47. Ruiz C, Lenkiewicz E, Evers L et al (2011) Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci U S A 108(29): 12054-12059.
48. Huang S, Gulzar ZG, Salari K et al (2012) Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene 31(37): 4164-4170.
49. Tomlins S, Rhodes D, Yu J et al (2008) The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 13(6): 519-528.
50. Ateeq B, Tomlins SA, Laxman B et al (2011) Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 3(72): 72ra17.
51. Gao N, Zhang J, Rao M et al (2003) The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol Endocrinol 17(8): 1484-1507.
52. Shin S, Kim T-D, Jin F et al (2009) Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. Cancer Res 69(20): 8102-8110.
53. Lin D, Fang H, Ma A et al (2004) Negative modulation of androgen receptor transcriptional activity by Daxx. Mol Cell Biol 24(24): 10529-10541.
54. Kwon JE, La M, Oh KH et al (2006) BTB domain-containing speckle-type POZ protein (SPOP) serves as an adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase. J Biol Chem 281(18): 12664-12672.
55. Li C, Ao J, Fu J et al (2011) Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Oncogene 30(42): 4350-4364.
56. Wang Q, Carroll JS, Brown M (2005) Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell 19(5): 631-642.
57. Pienta KJ, Bradley D (2006) Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12(6): 1665-1671.
58. Bismar T, Yoshimoto M, Duan Q (2012) Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer. Histopathology 60(4): 645-652.
59. Cai C, Balk SP (2011) Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr-Relat Cancer 18(5): R175-R182.
60. Andersen RJ, Mawji NR, Wang J et al (2010) Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17(6): 535-546.